Cargando…

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer

Lung cancer is the most common cancer and leading cause of cancer death. While targeted therapies have redefined treatment options for non-small cell lung carcinoma (NSCLC) with genetic aberrations such as epidermal growth factor and anaplastic lymphoma kinase, many patients do not harbour these onc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Low, Jia Li, Walsh, Robert J., Ang, Yvonne, Chan, Gloria, Soo, Ross A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716180/ https://www.ncbi.nlm.nih.gov/pubmed/31497071 http://dx.doi.org/10.1177/1758835919870360

Ejemplares similares

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)
por: Shibaki, Ryota, et al.
Publicado: (2021)

Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients
por: Gkountakos, Anastasios, et al.
Publicado: (2021)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis
por: Bilani, Nadeem, et al.
Publicado: (2021)

A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019)

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study
por: Dimitrakopoulos, Foteinos-Ioannis, et al.
Publicado: (2022)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
por: Xuzhang, Wendi, et al.
Publicado: (2023)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
por: Novello, Silvia, et al.
Publicado: (2023)

Hospital-based multidisciplinary lung cancer care in Australia: a survey of the landscape in 2021
por: Brims, Fraser J H, et al.
Publicado: (2022)

LDCT lung cancer screening in populations at different risk for lung cancer
por: Teles, Gustavo Borges da Silva, et al.
Publicado: (2020)

Management of Lung Cancer in the Patient with Interstitial Lung Disease
por: Frank, Angela J, et al.
Publicado: (2022)

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
por: Lammers, Austin, et al.
Publicado: (2018)

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
por: Lüchtenborg, Margreet, et al.
Publicado: (2014)

Evolving landscape and academic attitudes toward the controversies of global immuno‐oncology trials
por: Xu, Cheng, et al.
Publicado: (2021)

A Modified Calculation Improves the Accuracy of Predicted Postoperative Lung Function Values in Lung Cancer Patients
por: Schlachtenberger, G., et al.
Publicado: (2021)

Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients
por: Møller, Henrik, et al.
Publicado: (2018)

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
por: Tinker, Anna V., et al.
Publicado: (2023)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening
por: Field, J K, et al.
Publicado: (2016)

Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme
por: Lebrett, Mikey B, et al.
Publicado: (2020)

Prevalence and outcome of central airway obstruction in patients with lung cancer
por: Daneshvar, Cyrus, et al.
Publicado: (2019)

Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
por: Avancini, Alice, et al.
Publicado: (2019)

Evaluation of cardiovascular risk in a lung cancer screening cohort
por: Ruparel, Mamta, et al.
Publicado: (2019)

The Chest Australia Trial: a randomised controlled trial of an intervention to increase consultation rates in smokers at risk of lung cancer
por: Emery, Jon D, et al.
Publicado: (2019)

Responding to symptoms suggestive of lung cancer: a qualitative interview study
por: Birt, Linda, et al.
Publicado: (2014)

Diffuse Alveolar Hemorrhage in a Patient Receiving Bevacizumab for Lung Cancer
por: Sethi, Sakshi, et al.
Publicado: (2014)

Practical Guidance for the Management of Adverse Events in Patients with KRAS(G12C)-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
por: Zhang, Jun, et al.
Publicado: (2023)

Distribution and characterization of microplastics in marine sediments from the Montenegrin coast
por: Bošković, Neda, et al.
Publicado: (2022)

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022)

Psychological outcomes of low-dose CT lung cancer screening in a multisite demonstration screening pilot: the Lung Screen Uptake Trial (LSUT)
por: Kummer, Sonja, et al.
Publicado: (2020)

Image enhancement technology in bronchoscopy: a prospective multicentre study in lung cancer
por: van der Heijden, Erik H F M, et al.
Publicado: (2018)

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors
por: Lu, Shun, et al.
Publicado: (2019)

Defining the information needs of lung cancer screening participants: a qualitative study
por: Ruparel, Mamta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rh30t12g41575ef4d0ifr11ccf